202 related articles for article (PubMed ID: 27145388)
21. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
[No Abstract] [Full Text] [Related]
22. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Rivolo S; Di Fusco M; Polanco C; Kang A; Dhanda D; Savone M; Skandamis A; Kongnakorn T; Soto J
PLoS One; 2021; 16(11):e0259251. PubMed ID: 34767564
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
Mahmoudi M; Sobieraj DM
Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
[TBL] [Abstract][Full Text] [Related]
26. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
27. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
28. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Dranitsaris G; Shane L; Burgers L; Woodruff S
Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Migliaccio-Walle K; Rublee D; Simon TA
Postgrad Med; 2012 Jan; 124(1):41-9. PubMed ID: 22314113
[TBL] [Abstract][Full Text] [Related]
31. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Lanitis T; Kongnakorn T; Jacobson L; De Geer A
Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery.
Glickman A; Brennecke A; Tayebnejad A; Matsuo K; Guntupalli SR; Sheeder J
Gynecol Oncol; 2020 Nov; 159(2):476-482. PubMed ID: 32854972
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
Kimpton M; Kumar S; Wells PS; Coyle D; Carrier M; Thavorn K
CMAJ; 2021 Oct; 193(40):E1551-E1560. PubMed ID: 35040802
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation.
Lip GY; Lanitis T; Kongnakorn T; Phatak H; Chalkiadaki C; Liu X; Kuznik A; Lawrence J; Dorian P
Clin Ther; 2015 Nov; 37(11):2476-2488.e27. PubMed ID: 26477648
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
38. Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department.
Deitelzweig S; Hlavacek P; Mardekian J; Rosenblatt L; Russ C; Tuell K; Lingohr-Smith M; Lin J; Guo JD
Hosp Pract (1995); 2020 Feb; 48(1):41-48. PubMed ID: 31976776
[No Abstract] [Full Text] [Related]
39. Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients.
Bhalla V; Abdel-Latif A; Bhalla M; Ziada K; Williams MV; Smyth SS
Am J Cardiol; 2018 Oct; 122(7):1236-1243. PubMed ID: 30082040
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
